About Vero Biotech
Vero Biotech is a Healthcare company based in Atlanta (United States) founded in 2017. It operates as an inhaled nitric oxide systems are developed for cardiopulmonary treatments. Vero Biotech has raised $30 million across 2 funding rounds from investors including Runway Growth Capital and Petrichor. The company has 268 employees. Its chief executive is Brent V Furse. Vero Biotech offers products and services including GENOSYL Delivery System. Its focus areas include Life Sciences, Hospital Equipment, Hospital Infrastructure and Medical Gas Delivery. Its legal entity is VERO Biotech Inc. Its competitors include Sysadvance, Absstem, Genrich Membranes, Phortman and Tgpoxygen and 1 more; 1 of its 6 listed competitors has raised funding.
Company details
Vero Biotech was established in 2017 in Atlanta, United States, within the biotechnology sector. Inhaled nitric oxide delivery systems are developed by the company for cardiopulmonary applications. GeNOsyl is provided as a specialized system to address persistent pulmonary hypertension of the newborn (PPHN) accompanied by hypoxic respiratory failure. Operations focus on medical device innovation for neonatal care in the United States.
- Headquarters Atlanta, United States
- Employees 268
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website vero-biotech.com
- Social LinkedIn Facebook Instagram
- Legal Name Vero Biotech Inc
- Total Equity Funding$30M (USD)
in 2 rounds
- Latest Funding Round$30M (USD), Series B
Jan 2023
- InvestorsRunway Growth Capital
& 1 more
- Employee Count268
Products & Services of Vero Biotech
Vero Biotech offers a comprehensive portfolio of products and services, including GENOSYL Delivery System.
Tankless system for on-demand nitric oxide in pulmonary treatment.
Funding Insights of Vero Biotech
Vero Biotech has successfully raised a total of $30M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $30 million completed in January 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $30M
- Total Rounds 2
- Last Round Series B — $30M
- First Round $50M
(Jan 2021)
- Investors Count 2
All 2 funding rounds of Vero Biotech with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2023 | $30M | Series B | – | Petrichor | – |
| Jan 2021 | $50M | Debt – Conventional | – | – |
2 investors in total: 2 institutional.
Investors in Vero Biotech
Vero Biotech has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Runway Growth Capital and Petrichor.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Petrichor is engaged in supporting healthcare innovation through investments. | 2018 | petrichorcap.com | New York, USA | |
Venture debt financing is provided to companies across multiple sectors. | 2015 | runwaygrowth.com | Woodside, United States |
Investor details for Vero Biotech
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Vero Biotech
33 people are tracked at Vero Biotech (15 in leadership, 2 in board & advisors, 16 in team); the tracked headcount is 268.
| Name | Role | Group |
|---|---|---|
Brent V Furse | CEO & President | Leadership |
Migdalia Cruz | Supply Chain Director | Leadership |
Michelle Nickoli | VP, Customer Engagement | Leadership |
Namita Khanna | VP, Strategic Development | Leadership |
Levi A. | Senior Director Of Engineering, Software Architecture | Leadership |
Jeff Dail | Vice President Of Customer Engagement | Leadership |
Kyle Galenski | Director Of Commercial Operations And Marketing | Leadership |
Lucas Gamero | VP Of Engineering | Leadership |
Jonathan Powers | Vice President Of Manufacturing | Leadership |
Robert Hurtz | Senior Director Software Development | Leadership |
Jason Molinari | Senior Vice President Of New Product Development | Leadership |
Clayton Santiago | Senior Director Of Strategic Accounts And Marketing | Leadership |
Alex Layyous | Director, Console Engineering | Leadership |
Robyn McClure | Vp, Regulatory | Leadership |
Christopher D. Johnson | Director Of National Accounts | Leadership |
Daniel E Salazar | Director | Board & advisors |
Todd Brady | Director | Board & advisors |
Kimberly Cartus | Principal Systems Engineer | Team |
Kevin Stout | Sr. Account Executive | Team |
Sean McKinley | Warehouse Manager | Team |
13 more people are available in the full profile.
Complete people profiles for Vero Biotech
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Vero Biotech
3 dated milestones of Vero Biotech across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Vero Biotech is founded.
- Funding First funding round of $50.0M.
- Funding Latest funding round, Series B, of $30.0M.
Competitors of Vero Biotech
Vero Biotech has 6 listed competitors in our database, 1 of them funded. They include Sysadvance, Absstem, Genrich Membranes, Phortman and Tgpoxygen, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| sysadvance.com | 2002 | – | – | – | Developer of on-site gas generation and gas purifiers | |
| absstem.com | 2017 | Delhi, India | – | 38 | Produces PSA generators for medical oxygen and industrial nitrogen supply services. | |
| genrichmembranes.com | 2014 | Pune, India | $75,154 | 2 | Developer of oxygen enrichment unit | |
| phortman.com | 2011 | Ruurlo, Netherlands | – | – | Gas outlets for medical gas delivery | |
| tgpoxygen.com | 1993 | Wallingford, United States | – | – | Medical gases delivery systems and vacuum services are supplied. | |
| lexionmedical.com | 2000 | Minneapolis, United States | – | – | Develops advanced medical devices for surgical gas conditioning and visualization. |
Detailed competitors of Vero Biotech
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Vero Biotech
The website of Vero Biotech (vero-biotech.com) receives about 1.9K visits a month.
- Monthly visits1.9K
▼ 21% vs previous month
Top companies in Medical Equipment & Supplies
10 companies that operate in the same segment as Vero Biotech (Medical Equipment & Supplies), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Software and integrated solutions for surgical and radiotherapy applications | 1989 | Munchen, Bayern, Germany | USD 5.38 M | USD 1.18 M | 18 | |
Robotic waterjet system for prostate tissue removal is developed. | 2009 | Redwood City, California, United States | USD 348.84 M | USD 308.05 M | 756 | |
Collaborative surgical robotic systems are provided for hospital procedures. | 2014 | Cambridge, Cambridgeshire, United Kingdom | USD 1.68 B | USD 48.75 M | 680 | |
Robotic microsurgical systems for endoscopy are developed. | 2007 | Redwood City, California, United States | USD 733.62 M | – | 91 | |
Augmented reality systems for guiding surgical procedures are developed. | 2014 | Yokneam Illit, North District, Israel | USD 142.6 M | – | – | |
Manufacturer of imaging and surgical products | 1919 | Tokyo, Tokyo, Japan | – | USD 6.49 B | 35,933 | |
Injectable packaging, containment, and delivery solutions are manufactured. | 1923 | Exton, Pennsylvania, United States | – | USD 3.07 B | 10,600 | |
Rapid infusion systems are provided for critically ill patients. | 2012 | Durham, North Carolina, United States | USD 77.98 M | – | – | |
Mobile robots are manufactured for industries including healthcare and agriculture. | 2013 | Odense, Denmark | USD 81.44 M | – | 303 | |
Visualization systems for surgical procedures are developed using machine learning. | 2016 | Seattle, Washington, United States | USD 74.25 M | – | 52 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Vero Biotech
Complete news archive for Vero Biotech
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Vero Biotech
Vero Biotech was founded in 2017 and raised its 1st funding round 4 years after it was founded.
Vero Biotech is headquartered in Atlanta, United States. It is registered at Atlanta, Georgia, United States.
Brent V Furse is the current CEO of Vero Biotech.
Vero Biotech is a funded company, having raised a total of $30M across 2 funding rounds to date. The company's 1st funding round was a Debt – Conventional of $50M, raised on Jan 2021.
Vero Biotech has 268 employees.
Vero Biotech was established in 2017 in Atlanta, United States, within the biotechnology sector. Inhaled nitric oxide delivery systems are developed by the company for cardiopulmonary applications. GeNOsyl is provided as a specialized system to address persistent pulmonary hypertension of the newborn (PPHN) accompanied by hypoxic respiratory failure. Operations focus on medical device innovation for neonatal care in the United States.
Vero Biotech's top competitors include Absstem, Genrich Membranes and Sysadvance.
Vero Biotech offers GENOSYL Delivery System.
Vero Biotech has 2 investors. Key investors include Runway Growth Capital, and Petrichor.
Vero Biotech operates through Vero Biotech Inc.